TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36701184
Drug: Indigestion medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigestion medications
Study: 36701531
Drug: Mindful yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful yoga intervention (MYI) as add-on to treatment as usual (TAU)
Study: 36701613
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake ('fed') within 2 hours of the test
Study: 36701651
Drug: OBI-999 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-999 at 1.2 mg/kg every 21 days
Study: 36701651
Drug: OBI-999 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-999 at 1.6 mg/kg
Study: 36701797
Drug: Optimized acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized acute treatment of migraine
Study: 36702070
Drug: Neratinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib dose escalation over the first 2 weeks (DE1)
Study: 36702070
Drug: Neratinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib dose escalation over the first 4 weeks (DE2)
Study: 36702070
Drug: Loperamide (L)
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide (L)
Study: 36702070
Drug: Neratinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib treatment
Study: 36702138
Drug: G-CSF, decitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF, decitabine, and busulfan-cyclophosphamide conditioning
Study: 36702329
Drug: Mivavotinib 60-120
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivavotinib 60-120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity
Study: 36702934
Drug: Acyclovir administered
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir administered intravenously every 8 hours with a 1-hour infusion of 500 mg/m
Study: 36703109
Drug: Tablet-based electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based electronic decision-support system (EDSS) used by healthcare providers during ANC visits.
Study: 36703120
Drug: ADIVA (advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADIVA (advanced double intravenous vasopressor automated system)
Study: 36703120
Drug: DIVA (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIVA (double intravenous vasopressor automated system)
Study: 36703250
Drug: Immediate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intervention (8-session emotion and self-regulation group intervention with daily app-based prompts)
Study: 36704479
Drug: Yiqi Fumai
Normalized name: Aspergillus fumigatus allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Fumai lyophilized injection (YQFM)
Study: 36704634
Drug: Control (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (only pharmacological therapy)
Study: 36704737
Drug: PSYCHOPATHY.COMP program
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSYCHOPATHY.COMP program (20-session individual intervention based on Compassion Focused Therapy)
Study: 36704757
Drug: My Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: My Sleep Our Sleep (MSOS) intervention delivered weekly for 4 weeks
Study: 36704795
Drug: Micronutrient-containing supplement
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-containing supplement including zinc, taken preconception and throughout pregnancy until birth.
Study: 36705433
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for comorbid posttraumatic stress and substance use disorders
Study: 36705474
Drug: Intralesional PPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional PPD immunotherapy for the largest wart (Group A)
Study: 36705526
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks with enzalutamide 160 mg once daily and ADT
Study: 36705526
Drug: placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo every 3 weeks with enzalutamide 160 mg once daily and ADT
Study: 36705566
Drug: 145 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145 mg/day of nanocrystallized fenofibrate
Study: 36705924
Drug: SGM-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGM-101 (10 mg) infused up to 5 days before index operation.
Study: 36705941
Drug: Sodium phenylbutyrate-taurursodiol
Normalized name: sodium phenylbutyrate-taurursodiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phenylbutyrate-taurursodiol (PB-TURSO), a combination of 3 g of PB and 1 g of TURSO given twice daily.
Study: 36705941
Drug: AMX0035 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX0035 (a sachet containing a fixed co-formulation of 3 g of PB and 1 g of TURSO given twice daily).
Study: 36706645
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg twice daily during NACT
Study: 36706655
Drug: Niraparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (300 mg/day fixed starting dose or individualized starting dose according to baseline body weight and platelet count)
Study: 36706655
Drug: Individualized starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individualized starting dose (ISD) of niraparib
Study: 36706655
Drug: Fixed starting
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed starting dose of niraparib
Study: 36706675
Drug: In-person counselling
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person counselling (45-70 minutes, two sessions over three months) with interim monthly booster phone calls (live call arm)
Study: 36706675
Drug: In-person counselling
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person counselling (45-70 minutes, two sessions over three months) with twice-weekly automated booster sessions (technology arm)
Study: 36706754
Drug: Lentivirus-based gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentivirus-based gene therapy
Study: 36706754
Drug: Targeted treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatments to protect HSCs
Study: 36706958
Drug: Dose-escalated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated radiotherapy to the whole primary tumour
Study: 36706958
Drug: Dose-escalated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated radiotherapy to a PET-defined subvolume
Study: 36707080
Drug: Intensive antiplatelet
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Study: 36707080
Drug: Intensive antiplatelet
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90)
Study: 36707080
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Study: 36707080
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy plus delayed intensive statin therapy
Study: 36707808
Drug: Trifluridine/tipiracil (FTD/TPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (FTD/TPI) 35 mg/m²
Study: 36707841
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 20% hypertonic saline solution (HSS) to maintain blood sodium level between 150 and 155 mmol/L for at least 48 hours.
Study: 36708539
Drug: CCB use
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB use in single antihypertensive agent
Study: 36708539
Drug: CCB use
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB use in > 1 antihypertensive agent
Study: 36708650
Drug: Propolis (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (4 capsules of 100 mg/day for two months)
Study: 36708650
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules of 100 mg/day for two months)
Study: 36708732
Drug: High-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose protein (≥2·2 g/kg per day)
Study: 36708732
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose protein (≤1·2 g/kg per day)
Study: 36708734
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate treatment over 2 years
Study: 36708734
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment over 2 years
Study: 36708738
Drug: CIS43LS 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS 1 mg/kg intravenously
Study: 36708738
Drug: CIS43LS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS 5 mg/kg intravenously
Study: 36708738
Drug: CIS43LS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS 10 mg/kg intravenously
Study: 36708738
Drug: CIS43LS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS 5 mg/kg subcutaneously
Study: 36708738
Drug: CIS43LS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS 10 mg/kg subcutaneously
Study: 36708966
Drug: Multimedia tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia tablet
Study: 36709074
Drug: cAd3-Marburg vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAd3-Marburg vaccine (1×10^11 viral particles)
Study: 37517413
Drug: Momelotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib (200 mg orally once per day)
Study: 37517413
Drug: Danazol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (300 mg orally twice per day)
Study: 36709275
Drug: All BI
Normalized name: BISMUTH SUBSALICYLATE 262 mg ORAL TABLET, CHEWABLE [rexall bismuth]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All BI 425809 treatment groups
Study: 36710399
Drug: roxadustat 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat 2.0 mg/kg
Study: 36710399
Drug: roxadustat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat 2.5 mg/kg
Study: 36711070
Drug: Dermocosmetic (DC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermocosmetic (DC) applied twice daily for 28 days
Study: 36711127
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EPs (P3 and P10) and image-derived information
Study: 36711671
Drug: Friendship Bench
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendship Bench intervention (six weekly individual counselling sessions of problem-solving therapy)
Study: 36711869
Drug: Mifepristone (glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (glucocorticoid receptor antagonist)
Study: 36711869
Drug: Yohimbine (α2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (α2 receptor antagonist)
Study: 38491376
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention (EBI; protocol-based hypertension treatment)
Study: 36712824
Drug: Surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical debridement and hyperbaric oxygen therapy
Study: 36712888
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone
Study: 36712888
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with triple antiemetic therapy (fosaprepitant, ondansetron, and dexamethasone)
Study: 36713413
Drug: AZD1222 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 vaccine
Study: 36713761
Drug: Rivaroxaban plus
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban plus antiplatelet therapy (combination therapy)
Study: 36714040
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine administration (group K)
Study: 36714040
Drug: No ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ketamine administration (group NK)
Study: 36714197
Drug: Social app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Social app care group (warfarin therapy guided by experienced clinicians via a social app)
Study: 36714197
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care group (warfarin therapy managed through traditional in-office visits)
Study: 36715014
Drug: hTERT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hTERT vaccine UV1 combined with androgen deprivation therapy (ADT) and radiotherapy
Study: 36715152
Drug: Prasugrel dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel dose de-escalation (5 mg daily)
Study: 36715152
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (prasugrel 10 mg daily)
Study: 36715655
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressants and fear-avoidance rehabilitation
Study: 36715712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of crush injury, PT, and NEU
Study: 36716031
Drug: SER-109 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-109 (4 capsules once daily for 3 days)
Study: 36716310
Drug: Evidence-based practices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based practices including subglottic suctioning, daily assessment for spontaneous awakening trial (SAT), spontaneous breathing trial (SBT), head of bed elevation, and avoidance of neuromuscular blockers unless otherwise indicated.
Study: 36716382
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously plus SoC
Study: 36716759
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable (LAI) antipsychotics (paliperidone and aripiprazole)
Study: 36716759
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (paliperidone and aripiprazole)
Study: 36716759
Drug: Combined LAI
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined LAI treatment
Study: 36716759
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral treatment
Study: 36716759
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (LAI vs Oral)
Study: 36716761
Drug: Emicizumab 3
Normalized name: Emicizumab 30 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 3 mg/kg subcutaneously once weekly for 4 weeks, followed by maintenance doses of 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks.
Study: 36716780
Drug: Sex hormones
Normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormones (estrone, estradiol, testosterone, dehydroepiandrosterone)
Study: 36716780
Drug: Null findings
Normalized name: Nullo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Null findings for sex hormones
Study: 36716960
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions with concurrent i.v. cisplatin (75mg/m2)
Study: 36716960
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiotherapy of 60 Gy in 40 fractions with concurrent i.v. cisplatin (75mg/m2)
Study: 36717148
Drug: Active sTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sTMS treatment for 6 weeks
Study: 36717148
Drug: Sham sTMS
Normalized name: STM-217
DrugBank: STM-217 (DB17358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham sTMS treatment for 6 weeks
Study: 36717148
Drug: At-home sTMS
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home sTMS administration
Study: 36717150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipilimumab and nivolumab with SBRT (24 Gray in three fractions)
Study: 36717150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipilimumab and nivolumab without SBRT
Study: 36717150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipilimumab and nivolumab with SBRT
Study: 36717385
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with low-dose B vitamins plus betaine (400 μg folic acid, 8 mg vitamin B) for 12 weeks
Study: 36717539
Drug: Meplazumab 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meplazumab 0.12 mg/kg
Study: 36717539
Drug: Meplazumab 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meplazumab 0.2 mg/kg
Study: 36717539
Drug: Meplazumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meplazumab 0.3 mg/kg
Study: 36717556
Drug: Injectable intramuscular
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Study: 36718142
Drug: Avelumab 800
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg (days 1 and 8) + Cetuximab 250 mg/m2
Study: 36718142
Drug: Avelumab +
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab + Cetuximab + Chemotherapy
Study: 36718400
Drug: Hypnotic Analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic Analgesia (HAS)
Study: 36718624
Drug: Senaparib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib (oral, 100 mg daily in 3-week cycles)
Study: 36718994
Drug: Sham electrodes
Normalized name: ELECTRODE ELECTROLYTE SPRAY,TOP,PMT#CS4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electrodes as placebo treatments
Study: 36718994
Drug: Topical gels
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gels as placebo treatments
Study: 36719104
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily + metronidazole 400 mg three times daily)
Study: 36719104
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily)
Study: 36720083
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once-daily for 3 years
Study: 36720090
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa monotherapy
Study: 36720133
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efanesoctocog alfa on-demand treatment for 26 weeks followed by prophylaxis for 26 weeks in group B
Study: 36720570
Drug: FOLFOXIRI (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI (5-fluorouracil, oxaliplatin, and irinotecan) for four cycles as neoadjuvant chemotherapy (NAC)
Study: 36720576
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg semaglutide once a week
Study: 36721157
Drug: L-GF injection
Normalized name: remestemcel-L Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-GF injection
Study: 36721157
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L-GF and Control)
Study: 36721920
Drug: 260 IU
Normalized name: acetaminophen 260 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 260 IU recombinant hCG (rhCG) daily injections for 8 weeks
Study: 36721963
Drug: Inhaled siR-7-EM/KK-46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled siR-7-EM/KK-46 (3.7 mg/day)
Study: 36721963
Drug: Inhaled siR-7-EM/KK-46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled siR-7-EM/KK-46 (11.1 mg/day)
Study: 36721963
Drug: Standard etiotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard etiotropic drug treatment (control group)
Study: 36722133
Drug: DAAs (direct-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAs (direct-acting antivirals)
Study: 36722147
Drug: RSVPreF3 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 (60 µg)
Study: 36722147
Drug: RSVPreF3 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 (120 µg)
Study: 36723678
Drug: Axi-cabtagene ciloleucel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axi-cabtagene ciloleucel (axi-cel); chimeric antigen receptor T-cell therapy
Study: 38939456
Drug: Tafamidis (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis (80 mg or 20 mg)